arrow
J

Jordan R. Hansford

Royal Children's Hospital
H指数:45
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

H3K27M Mutation Modulates the Antigenic Landscape in Diffuse Midline Glioma

中线弥漫性胶质瘤中H3K27M突变调控抗原景观

Cancers
IF4.4
2026-09-290
OA
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma

适度乐观:精准医学时代儿童低级别胶质瘤的进展

2026-05-190
PRE
Precision-guided therapy in H3K27-altered diffuse midline glioma

H3K27-改变的弥漫性中线胶质瘤中的精准导向疗法

2026-05-190
OAAI
Molecular and Clinical Stratification of Astroblastomas: Three distinct Fusion-Defined Groups Informing Risk-Adapted Treatment Strategies

星形细胞瘤的分子和临床分层: 三个不同的融合定义组告知适应风险的治疗策略

2025-12-220
OA
Disseminated pediatric low-grade glioma and hydrocephalus: a multinational consortium analysis of incidence and mortality

播散性儿科低级别胶质瘤和脑积水:一项跨国联盟对发病率和死亡率的分析

2025-12-120
PRE
Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma

整合的播散性儿童低级别胶质瘤临床与分子全景

2025-10-210
PRE
Peripheral blood DNA methylation predicts the early onset of primary tumor in TP53 mutation carriers

外周血DNA甲基化预测TP53突变携带者中主肿瘤的早期发生

2025-08-260
OAAI
Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted, and TERTp-wildtype: A grade 1 oligodendroglioma of young patients?

少突胶质细胞瘤,IDH突变型,1p/19q共缺失和TERTp野生型的独特分子特征与预后:是年轻患者的1级少突胶质细胞瘤?

2025-08-010
PRE
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2025-04-160
OA
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

在FIREFLY-1试验中,托瓦雷芬尼(tovorafenib)这种II型RAF抑制剂对复发性/难治性视神经通路胶质瘤患儿的放射学和视觉反应。

2024-12-190
PRE
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
2024-11-110
PRE
MOLECULAR SUBTYPES, CLINICAL CHARACTERISTICS, AND THERAPEUTIC IMPLICATIONS FOR CNS TUMORS WITH BCOR/BCORL1 FUSION/INTERNAL TANDEM DUPLICATION
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
2024-11-110
PRE